NASDAQ:INTS Intensity Therapeutics Q4 2025 Earnings Results & Report $3.06 -0.02 (-0.49%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Intensity Therapeutics reported Q4 2025 earnings on March 27, 2026. The company reported EPS of -$0.31. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 27, 2026TimeAfter Market ClosesConference Call7:00 AM ET Intensity Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersIntensity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Intensity Therapeutics Q4 2025 Earnings FAQ Did Intensity Therapeutics beat earnings estimates for Q4 2025? Intensity Therapeutics (NASDAQ:INTS) reported earnings of -$0.31 per share for Q4 2025. The report was announced on Friday, March 27, 2026. Intensity Therapeutics Earnings HeadlinesWhat is HC Wainwright's Estimate for INTS FY2026 Earnings?November 12, 2026 | americanbankingnews.comBrookline Capital Markets Forecasts INTS FY2026 EarningsNovember 12, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call TranscriptNovember 7, 2026 | seekingalpha.comIntensity (INTS) Q3 2026 Earnings Call TranscriptNovember 5, 2026 | finance.yahoo.comIntensity Therapeutics, Inc Loss At -$3.544 Mln In Q3November 5, 2026 | rttnews.comSee More Intensity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email. Email Address About Intensity TherapeuticsIntensity Therapeutics (NASDAQ:INTS), Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response. The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors. Founded in 2012, Intensity Therapeutics is led by founder and Chief Executive Officer Lewis Barger. Its work is focused on developing and clinically testing its intratumoral treatment platform.View Intensity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.